Bendamustine (Treanda®, Bendeka®, Belrapzo®, Vivimusta™) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 (TTY: 711)
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy, Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:	DOB:	
Address:	City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	Email:
Patient Current Weight: _____ lbs or _____ kgs Patient Height: _____ inches or _____ cms		Allergies:	

B. INSURANCE INFORMATION

Aetna Member ID #: _____ **Group #**: _____ **Insured**:	Does patient have other coverage? ☐ Yes ☐ No If yes, provide ID#: _____ Carrier Name: _____ Insured:

Medicare: ☐ Yes ☐ No If yes, provide ID #: **Medicaid:** ☐ Yes ☐ No If yes, provide ID #:

C. PRESCRIBER INFORMATION

First Name:		Last Name:		*(Check One)*: ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.	
Address:		City:		State:	ZIP:
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:		Office Contact Name:		Phone:	

Specialty *(Check one)*: ☐ **Oncologist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other _____
Name: _____
Address: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____

E. PRODUCT INFORMATION

Request is for: ☐ **Treanda** ☐ **Bendeka** ☐ **Belrapzo** ☐ **Vivimusta** ☐ **bendamustine**
Dose: _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other where applicable.

Primary ICD Code: ☐ _____ **Secondary ICD Code:** _____ **Other ICD Code:** _____

G. CLINICAL INFORMATION - Required clinical information must be completed in its entirety for all precertification requests.

For Initiation Requests (Clinical documentation required for all requests):

☐ **Adult T-cell leukemia/lymphoma (ATLL)**
☐ Yes ☐ No Will the requested drug be used as a single agent?
Please indicate the place in therapy in which the requested drug will be used: ☐ First-line therapy ☐ Subsequent therapy

☐ **Breast implant associated anaplastic large cell lymphoma (ALCL)**
☐ Yes ☐ No Will the requested drug be used as a single agent?
Please indicate the place in therapy in which the requested drug will be used: ☐ First-line therapy ☐ Subsequent therapy

☐ **Chronic lymphocytic leukemia (CLL) without chromosome 17p deletion or without TP53 mutation**

☐ **Cold agglutinin disease**
☐ Yes ☐ No Will the requested drug be used in combination with rituximab?

Continued on next page

Bendamustine (Treanda, Bendeka, Belrapzo, Vivimusta) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 (TTY: 711)
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

☐ **Classical Hodgkin lymphoma (cHL)**
- ☐ Yes ☐ No Will the requested drug be used as subsequent therapy or palliative therapy?

Please indicate the requested regimen:
- ☐ The requested drug will be used as a single agent
- ☐ The requested drug will be used in combination with brentuximab vedotin (Adcetris)
- ☐ The requested drug will be used in combination with gemcitabine and vinorelbine
- ☐ The requested drug will be used in combination with carboplatin and etoposide
- ☐ Other

☐ **Diffuse large B-cell lymphoma (DLBCL)**

Please indicate the place in therapy in which the requested drug will be used: ☐ First-line therapy ☐ Subsequent therapy
- ☐ Yes ☐ No Will the requested drug be used as a bridging option until CAR T-cell product is available?
  - → ☐ Yes ☐ No Is the patient a candidate for transplant?

Please indicate the requested regimen:
- ☐ The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy)
- ☐ The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy) and rituximab
- ☐ Other

☐ **Follicular lymphoma**

☐ **Hematopoietic cell transplantation**
- ☐ Yes ☐ No Will the requested drug be used as conditioning for autologous transplant?
- ☐ Yes ☐ No Will the requested drug be used in combination with etoposide, cytarabine and melphalan?

☐ **Hepatosplenic T-Cell Lymphoma**
- ☐ Yes ☐ No Will the requested drug be used as a single agent?

Please indicate the clinical setting in which the requested drug will be used: ☐ Refractory ☐ Other
- ☐ Yes ☐ No Has the patient received TWO first-line therapy regimens?

☐ **High grade B-cell lymphoma**

Please indicate the place in therapy in which the requested drug will be used: ☐ First-line therapy ☐ Subsequent therapy
- ☐ Yes ☐ No Will the requested drug be used as a bridging option until CAR T-cell product is available?
  - → ☐ Yes ☐ No Is the patient a candidate for transplant?

Please indicate the requested regimen:
- ☐ The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy)
- ☐ The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy) and rituximab
- ☐ Other

☐ **Histologic transformation of indolent lymphomas to diffuse large B-cell lymphoma**

Please indicate the requested regimen:
- ☐ The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy)
- ☐ The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy) and rituximab
- ☐ Other

Please indicate the place in therapy in which the requested drug will be used: ☐ First-line therapy ☐ Subsequent therapy
- ☐ Yes ☐ No Is the patient a candidate for transplant?

☐ **HIV-related B-cell lymphoma (HIV-related diffuse large B-cell lymphoma, primary effusion lymphoma, and human herpesvirus-8 (HHV8) positive diffuse large B-cell lymphoma, plasmablastic lymphoma)**

Please indicate the place in therapy in which the requested drug will be used: ☐ First-line therapy ☐ Subsequent therapy
- ☐ Yes ☐ No Will the requested drug be used as a bridging option until CAR T-cell product is available?
  - → ☐ Yes ☐ No Is the patient a candidate for transplant?

Please indicate the requested regimen:
- ☐ The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy)
- ☐ The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy) and rituximab
- ☐ Other

☐ **Mantle cell lymphoma (MCL)**

Please indicate the requested regimen:
- ☐ The requested drug will be used in combination with rituximab
- ☐ The requested drug will be used as a component of RBAC500 (rituximab, bendamustine, and cytarabine)
- ☐ Other

Continued on next page

Bendamustine (Treanda, Bendeka, Belrapzo, Vivimusta) Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 (TTY: 711)
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

☐ **Marginal zone lymphoma [nodal, gastric MALT (extranodal marginal zone lymphoma of the stomach), non-gastric MALT (nongastric extranodal marginal zone lymphoma), splenic]**
Please indicate the requested regimen:
- ☐ The requested drug will be used in combination with rituximab
- ☐ The requested drug will be used in combination with obinutuzumab (Gazyva)
- ☐ Other

☐ **Multiple myeloma**
Please indicate the requested regimen:
- ☐ The requested drug will be used as a single agent
- ☐ The requested drug will be used in combination with lenalidomide (Revlimid) and dexamethasone
- ☐ The requested drug will be used in combination with bortezomib (Velcade) and dexamethasone
- ☐ The requested drug will be used in combination with carfilzomib and dexamethasone
- ☐ Other

Please indicate the clinical setting in which the requested drug will be used: ☐ Relapsed ☐ Progressive ☐ Other
☐ Yes ☐ No Has the patient tried more than 3 prior therapies?

☐ **Nodular Lymphocyte Predominant Hodgkin lymphoma (NLPHL)**
Please indicate the place in therapy in which the requested drug will be used: ☐ First-line therapy ☐ Subsequent therapy
☐ Yes ☐ No Will the requested drug be used in combination with rituximab?

☐ **Post-transplant lymphoproliferative disorders**
Please indicate the place in therapy in which the requested drug will be used: ☐ First-line therapy ☐ Subsequent therapy
☐ Yes ☐ No Will the requested drug be used as a bridging option until CAR T-cell product is available?
→ ☐ Yes ☐ No Is the patient a candidate for transplant?
Please indicate the requested regimen:
- ☐ The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy)
- ☐ The requested drug will be used in combination with polatuzumab vedotin-piiq (Polivy) and rituximab
- ☐ Other

☐ **Peripheral T-cell Lymphoma (PTCL) [including the following subtypes: anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, enteropathy associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, nodal peripheral T-cell lymphoma with TFH phenotype, or follicular T-cell lymphoma]**
☐ Yes ☐ No Will the requested drug be used as a single agent?
☐ Yes ☐ No Will the requested drug be used as palliative or subsequent therapy?

☐ **Small lymphocytic lymphoma (SLL) without chromosome 17p deletion or without TP53 mutation**

☐ **Systemic light chain amyloidosis**
☐ Yes ☐ No Will the requested drug be used in combination with dexamethasone?
Please indicate the clinical setting in which the requested drug will be used: ☐ Relapsed disease ☐ Refractory disease ☐ Other

☐ **Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma/Bing-Neel syndrome**
Please indicate the requested regimen:
- ☐ The requested drug will be used as a single agent
- ☐ The requested drug will be used in combination with rituximab
- ☐ Other

For Continuation Requests (clinical documentation required for all requests):
☐ Yes ☐ No Is there evidence of unacceptable toxicity or disease progression while on the current regimen?

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required)*: _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties

The plan may request additional information or clarification, if needed, to evaluate requests.